Investigational drug · Phase 2
MRT-2359
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer, NSCLC, SCLC.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "MRT-2359"
First trial start
2022
Oct 12, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MRT-2359", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer
- NSCLC
- SCLC
- High Grade Neuroendocrine Cancer
- DLBCL
- L-MYC and N-MYC Amplified Solid Tumors
- NSCLC With High or Low L-MYC or N-MYC Expression
- HR-positive, HER2-negative Breast Cancer
- Castration-Resistant Prostate Cancer (CRPC)
- Castration-Resistant Prostate Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "MRT-2359" as an intervention, largest first.
- Study of Oral MRT-2359 in Selected Cancer PatientsActive, not recruiting
Monte Rosa Therapeutics, IncIndustry
NCT05546268 · 174 participants (planned) · Start Oct 12, 2022 · Primary completion Dec 2026
Drug: Oral MRT-2359; Oral MRT-2359 and 4 more · For: NSCLC; SCLC; High Grade Neuroendocrine Cancer and 5 more
Sites: Scottsdale, Arizona; San Diego, California; New Haven, Connecticut · 17 sites in all
Monte Rosa Therapeutics, IncIndustry
NCT07745361 · 25 participants (planned) · Start Aug 18, 2026 · Primary completion Oct 2027
Drug: Oral MRT-2359; Apalutamide · For: Castration-Resistant Prostate Cancer (CRPC); Castration-Resistant Prostate Cancer; Prostate Cancer and 1 more
Sites: Los Angeles, California; Newport Beach, California; Colorado Springs, Colorado · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Development of XYD113 as a potent and highly selective GSPT1 degrader for cancer therapy.
Shen H, Luo XY, Jing XY, et al. · Acta Pharmacol Sin 2026
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.